Wenxin Qin’s team found that targeting the mitochondrial translation process (e.g., tigecycline) could inhibit the growth of hepatocellular carcinoma, but the activation of the EGFR-ERK1/2 pathway-mediated resistance, and the combination of MEK/EGFR inhibitors could enhance the therapeutic efficacy significantly (Zhou et al., 2023). Here, EGFR is linked to hepatocellular carcinoma.